Salute e Benessere

Hydraulics Market worth $50.5 billion by 2028 - Exclusive Report by…

Browse in-depth TOC on "Hydraulics Market"150 – Tables50 – Figures200 – Pages Browse in-depth TOC on "Hydraulics Market" 150 – Tables 50 – Figures 200 – Pages Hydraulics Market Report Scope: Cylinders segment to hold the largest size of the hydraulics market during the forecast period. The cylinders segment is expected to account for the largest size of the hydraulics market throughout the forecast period. Hydraulic cylinders are integral components within the...
PR Newswire
21/12/2023

Veterinary Imaging Market Worth $2.9 billion | MarketsandMarkets

Browse in-depth TOC on "Veterinary Imaging Market" Browse in-depth TOC on "Veterinary Imaging Market" 250 - Tables 70 - Figures 320 - Pages Veterinary Imaging Market Scope: Advancements in CT and ultrasound technology are also opening doors for more precise diagnoses and minimally invasive procedures. Specialization within veterinary medicine is creating a demand for imaging solutions tailored to specific needs, like equine or avian imaging. Remote patient monitoring...
PR Newswire
21/12/2023

MSD Gulf Awarded Medical Education Partner of the Year by Emirates Oncology…

Commenting on the achievement, Professor Humaid Al Shamsi, President of the Emirates Oncology Society, said: "We are pleased to honor MSD, acknowledging their steadfast dedication to advancing healthcare through the development of innovative educational and multidisciplinary programs. This recognition underscores MSD's dedication to improving healthcare standards and outcomes, ultimately benefiting patients and the medical community. We look forward to continuing our collaborative efforts…
PR Newswire
21/12/2023

New Illuma Growing-up Infant Formula Now Available throughout China

Wyeth Nutrition 's long-term dedication and solid research foundation in this area allowed them to become the first multinational company to debut this innovative product in China. Over the course of its 30-year research career, it has undertaken 55 HMO-related studies, completed over 30 clinical trials, published over 70 research papers on the subject, and been given over 100 patents connected to HMOs. With the addition of six crucial HMOs, the company's most recent infant formula product…
PR Newswire
21/12/2023

Northwest Biotherapeutics Announces That A Marketing Authorization Application…

The MAA seeks approval for commercialization of DCVax-L for both newly diagnosed and recurrent glioblastoma (GBM). The application also requests to be considered under the MHRA's rapid 150-day review pathway, which the agency has established for new medicines for serious unmet medical needs. The MAA seeks approval for commercialization of DCVax-L for both newly diagnosed and recurrent glioblastoma (GBM). The application also requests to be considered under the MHRA's rapid 150-day review...
PR Newswire
21/12/2023

XRP Healthcare Appoints Digital Healthcare Evangelist and Isansys Founder Keith…

Isansys has collaborated with healthcare institutions, and organisations, and supported many clinical research trials, most notably its collaboration with the NHS (National Health Service) to deploy the PSE into hospital and home care settings. These partnerships aim to improve patient care, enable early intervention, and enhance healthcare efficiency. Isansys has collaborated with healthcare institutions, and organisations, and supported many clinical research trials, most notably its...
PR Newswire
21/12/2023

Nexstim Plc's Financial Information in 2024 and Updated Disclosure Policy

Nexstim Plc's Financial Information in 2024 and Updated Disclosure Policy Company Announcement, Helsinki, 21 December 2023 at 4 PM (EET) Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") announces that it will publish the following financial information in 2024:The 2023 Financial Statements Release and Half-Yearly Report July−December 2023 (H2) on Tuesday, February 27, 2024. Half-Yearly Report January-June 2024 (H1) on Friday, August 16, 2024.Nexstim's Annual Report 2023 will…
Nasdaq GlobeNewswire
21/12/2023

BioNTech and DualityBio Receive FDA Breakthrough Therapy Designation for…

Designation is based on Phase 1/2 safety and efficacy data in patients with Human Epidermal Growth Factor Receptor 2 (“HER2”)-expressing advanced endometrial cancer with encouraging early signs of anti-tumor activityBreakthrough Therapy designation will allow for an expedited development and regulatory review of BNT323/DB-1303Endometrial or uterine cancer is the second most common gynecologic cancer globally with over 400,000 cases occurring each year MAINZ, Germany and...
Nasdaq GlobeNewswire
21/12/2023

PureHealth shares settled a staggering 76% above listing price in Abu Dhabi…

Farhan Malik, Founder and Managing Director of PureHealth rang the ADX market opening bell to celebrate the listing, in the presence of H.E. Ahmed Jasim Al Zaabi, Chairman of Abu Dhabi Department of Economic Development, H.E Syed Basar Shueb, CEO and Managing Director of International Holding Company, H.E. Ghannam Al Mazrouei, Secretary-General of the Emirati Talent Competitiveness Council, H.E. Sultan Al Hemeiri Board Member of Alpha Dhabi Holding, Ms. Shaista Asif, Co-founder and Group CEO of…
PR Newswire
21/12/2023

Groupe Casino: Convening of Casino shareholders and creditors as affected…

Convening of Casino shareholders and creditors as affected parties to vote on the accelerated safeguard plansAvailability of the draft accelerated safeguard plansUpdate of the Consortium's business plan Paris, 21 December 2023Convening the classes of affected partiesBy judgments dated 25 October 2023, the Commercial Court of Paris ruled in favor of Casino's request and opened accelerated safeguard proceedings in its favor and in favor of certain of its subsidiaries 1for a...
Nasdaq GlobeNewswire
21/12/2023

Hadean Ventures announces oversubscribed final close of Hadean Capital II - a…

Walter Stockinger, Managing Partner, added, "With the new fund we are in an excellent position to leverage on the huge potential that we see in the European life science ecosystem. We are building on our successful strategy for Hadean Capital I, investing in start-up companies in different stages of development and across modalities and indications." Walter Stockinger, Managing Partner, added, "With the new fund we are in an excellent position to leverage on the huge potential…
PR Newswire
21/12/2023

LIfT BioSciences appoints Dr Bo Rode Hansen and Dr Marco Gottardis to its Board…

LIfT BioSciences appoints Dr Bo Rode Hansen and Dr Marco Gottardis to its Board of DirectorsLondon, 21 December 2023– LIfT BioSciences, ('LIfT' or 'the Company'), a rapidly emerging biotech company bringing to market a first-in-class allogeneic innate cell therapy, today announces the appointments of Dr Bo Rode Hansen PhD, MBA and Dr Marco Gottardis, PhD as Non-Executive Directors of its Board.Bo brings over two decades of transformational leadership experience involving general...
Nasdaq GlobeNewswire
21/12/2023

Nexstim Receives Order for Two NBS 6 Systems from Distributor

Press release, Helsinki, 21 December 2023 at 9 AM (EET) Nexstim Receives Order for Two NBS 6 Systems from Distributor Nexstim Plc (NXTMH:HEX) (“ Nexstim ” or “ Company ”) announces having received an order for two NBS 6 systems from a distributor company.Nexstim released the NBS 6 system earlier in 2023 in the EU and the United States. Developed in collaboration with Nexstim's customers, the NBS 6 system makes the company's clinically established, e-field navigated TMS (transcranial...
Nasdaq GlobeNewswire
21/12/2023

Press Release: Sanofi announces end of program evaluating tusamitamab ravtansine…

Sanofi announces end of program evaluating tusamitamab ravtansine after a 2L NSCLC Phase 3 trial did not meet a primary endpoint CARMEN-LC03 trial did not meet dual primary endpoint of improving progression-free survival; tusamitamab ravtansine clinical development program will be discontinuedSanofi reinforces commitment to broader oncology development program including CEACAM5-directed antibody drug conjugates (ADC) with additional anticipated trials PARIS, December 21, 2023...
Nasdaq GlobeNewswire
21/12/2023

IBA signs contract for a Proteus®ONE proton therapy system to be located at the…

Louvain-La-Neuve, Belgium, December 21, 2023 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world's leading provider of proton therapy solutions for the treatment of cancer, today announces it has signed a contract with Health Technologies Sp. z o.o. (Health Technologies) for the supply of a Proteus ® ONE 1compact proton therapy system to be delivered at the Greater Poland Cancer Center (Wielkopolskie Centrum Onkologii) in...
Nasdaq GlobeNewswire
21/12/2023

Discover the next frontier in Sleep Technology: INDIA MATTRESSTECH + UPHOLSTERY…

The Apex of Industry Advancement in India The Apex of Industry Advancement inIndia With industry predictions estimating a remarkable growth trajectory for the Indian Mattress Industry at2.4 billion USDand an expected Compound Annual Growth Rate (CAGR) of 7.97%, coupled with a corresponding 7% CAGR for the Upholstered Furniture Market between 2023-27, the sector is poised for substantial expansion. With a projected working-age population of 1.04 billion by 2030,Indiais fueled...
PR Newswire
21/12/2023

BGI Genomics Empowers Middle East Healthcare with Precision Medicine

Genalive offers a comprehensive range of tests, including prenatal, postnatal, inherited, and cancer genetics, as well as clinical pathology services such as hematology and immunology. Testing and sample processing are localized within Saudi Arabia, further enhancing affordability and future innovative applications. Genalive offers a comprehensive range of tests, including prenatal, postnatal, inherited, and cancer genetics, as well as clinical pathology services such as hematology and…
PR Newswire
21/12/2023

Metastatic Castration-Resistant Prostate Cancer Market is Predicted to Exhibit…

Key Takeaways from the Metastatic Castration-Resistant Prostate Cancer Market Report Key Takeaways from the Metastatic Castration-Resistant Prostate Cancer Market Report Discover which therapies are expected to grab the major mCRPC market share @ Metastatic Castration-Resistant Prostate Cancer Market Report Metastatic Castration-Resistant Prostate Cancer Overview Castration-resistant prostate cancer (CRPC) represents an advanced stage of prostate cancer. In the context of...
PR Newswire
20/12/2023

Calliditas Therapeutics announces full FDA approval of TARPEYO®, the only…

The approval is based on data from the Company's Phase 3 NefIgArd clinical trial, a randomized, double-blind, multicenter, study that assessed the efficacy and safety of TARPEYO dosed at 16 mg once daily versus placebo on a background of optimized RASi therapy in adult patients with primary IgAN. The approval is based on data from the Company's Phase 3 NefIgArd clinical trial, a randomized, double-blind, multicenter, study that assessed the efficacy and safety of TARPEYO dosed at 16 mg once...
PR Newswire
20/12/2023

Jazz Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare…

About Jazz PharmaceuticalsJazz Pharmaceuticals plc (NASDAQ: JAZZ) is a global biopharmaceutical company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with serious diseases—often with limited or no therapeutic options. We have a diverse portfolio of marketed medicines and novel product candidates, from early- to late-stage development, in neuroscience and oncology. Within these therapeutic…
PR Newswire
20/12/2023

Notice to Extraordinary General Meeting in Metacon AB (publ)

A shareholder who wish to participate in the general meeting must: A shareholder who wish to participate in the general meeting must: Nominee registered shares Shareholders whose shares are held in the name of a nominee must, in order to be able to participate at the general meeting and exercise their voting right, temporarily re-register the shares in their own name in the share register maintained by Euroclear Sweden AB (so-called voting right registration). When preparing the share...
PR Newswire
20/12/2023

Inventiva announces the randomization of the first patient in China in the…

The first patient was randomized in China in the NATiV3 Phase III clinical trial, triggering a milestone payment of $3 million from CTTQ to Inventiva. With this milestone payment Inventiva expects to have met the operational and financial conditions precedent to draw the second €25 million tranche of the EIB loan. 1 China's National Medical Products Administration has granted “Breakthrough Therapy Designation” to lanifibranor for the treatment of NASH. Lanifibranor is believed to be...
Nasdaq GlobeNewswire
20/12/2023

WGSN trends forecasters have 'Hormonal Skincare' predicted as a big beauty trend…

Living M is another brand paving the way when it comes to hormonal based beauty, with its skincare line designed for those experiencing peri/menopause. "Hormonal shifts in menopause have also been found to have a greater impact on skin than that of chronological ageing. Fluctuating hormones causes skin cell turnover to rapidly decline and can lead to concerns such as dryness, irritation, and breakouts," explains Living M Co-founder, Siobhan McCarthy. Living M is another brand paving…
PR Newswire
20/12/2023

EssilorLuxottica: Disclosure of Share Capital and Voting Rights Outstanding as…

Disclosure of Share Capital and Voting Rights Outstandingas of November 30, 2023(Pursuant to Article L.233-8 II of the French Commercial Code and articles 221-1 and 223-16 of the General Regulations of the Autorité des Marchés Financiers)Charenton-le-Pont, France (December 20, 2023 - 6:00 pm)– As of November 30, 2023, shares and voting rights outstanding of EssilorLuxottica, the global leader in the design, manufacture and distribution of ophthalmic lenses, frames and...
Nasdaq GlobeNewswire
20/12/2023
Altri  Comunicati